Dains advise on Team Consulting buyout
Dains Corporate Finance has acted as lead advisor on a recent deal which saw the employee buy-out of Team Consulting Ltd, a globally renowned expert in the design and development of medical devices. One of the better known medical devices designed by the Company is the Epipen, an autoinjector used for the emergency treatment of life-threatening allergic reactions (anaphylaxis).
The buy-out was led by Team Consulting's Chief Executive Officer, Dan Flicos, and Chief Operating Officer, Colin Mathews, and involved over 80 per cent of staff buying equity in the company. Established in 1986, Team has grown its expertise in engineering, design and human factors to deliver independent and commercially successful product development services to clients. The original founder and current chairman, who had both played a key role in Team’s history, wanted to profit from their years of effort and investment and it was important to Team that ownership remained with the staff and was open to everybody.
The Corporate Finance team advised the key stakeholders throughout the deal and tax advice was also provided by Dains.
"Team’s growth has been built on their uncompromising approach to high quality products and involving all staff in the business. This professionalism has resulted in this complex deal that meets the needs of the numerous stakeholders whilst maintaining the ethos and culture which is so critical to the success of the business.”